Compare BRID & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRID | GNTA |
|---|---|---|
| Founded | 1932 | 2014 |
| Country | United States | Italy |
| Employees | N/A | 9 |
| Industry | Specialty Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.7M | 69.4M |
| IPO Year | 1995 | N/A |
| Metric | BRID | GNTA |
|---|---|---|
| Price | $6.59 | $1.65 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.4K | ★ 139.7K |
| Earning Date | 06-01-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $174,257,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.21 | N/A |
| 52 Week Low | $6.35 | $0.55 |
| 52 Week High | $8.62 | $10.00 |
| Indicator | BRID | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 46.62 | 53.14 |
| Support Level | $6.48 | $1.30 |
| Resistance Level | $8.11 | $1.70 |
| Average True Range (ATR) | 0.26 | 0.12 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 42.73 | 64.06 |
Bridgford Foods Corp manufactures, markets, and distributes frozen and snack food products in the United States. The two business segments are: the processing and distribution of frozen products, and the processing and distribution of snack food products. Its product offerings include meat snacks, breads and rolls, biscuits, and ready-to-eat sandwiches, among others. The company offers frozen food products to the foodservice and retail customers through wholesalers, cooperatives, and distributors; and snack food items to supermarkets, mass merchandise, and convenience retail stores through customer-owned distribution centers, as well as a direct store delivery network. A majority of the company's revenue is derived from the snack food products segment.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon, a product to treat glioblastoma multiforme, a solid tumor affecting the brain.